| Tice BCG (live attenuated bacillus Calmette-Guerin) / Merck (MSD), Texas A&M University |
| Active, not recruiting | 3 | 516 | Europe | BCG, Bacillus Calmette Guerin (BCG) Medac®, OncoTice, Atezolizumab, MPDL3280A, Tecentriq® | UNICANCER, Hoffmann-La Roche | Bladder Cancer | 10/24 | 10/28 | | |
BCG+MMC, NCT02948543: Adding Mitomycin to BCG as Adjuvant Intravesical Therapy for High-risk Non-Muscle-invasive Bladder Cancer |
|
|
| Active, not recruiting | 3 | 501 | Europe, RoW | Bacillus of Calmette-Guerin (BCG), OncoTICE, ImmuCYST, TheraCys, Mitomycin (MM) | University of Sydney, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Cancer Australia | Bladder Cancer | 12/24 | 12/24 | | |
NCT03091660: S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer |
|
|
| Active, not recruiting | 3 | 1000 | US | BCG Solution, Bacillus Calmette-Guerin Solution, TICE BCG Solution, BCG Tokyo-172 Strain Solution, Bacillus Calmette-Guerin Tokyo-172 Strain Solution, Immunobladder, BCG Tokyo-172 Strain Vaccine, Bacillus Calmette-Guerin Tokyo-172 Strain Vaccine, Laboratory Biomarker Analysis | SWOG Cancer Research Network, National Cancer Institute (NCI) | Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma | 12/24 | 02/25 | | |
NCT03664869: Electromotive Mitomycin-C (EMDA-MMC) in Preventing Recurrences in High-risk Non-muscle-invasive Bladder Cancer |
|
|
| Recruiting | 3 | 300 | Europe | BCG instillation therapy, BCG, BCG-MEDAC, OncoTICE, ImmuCyst, TheraCys, Sequential BCG and EMDA mitomycin C, Sequential BCG and EMDA-MMC | Turku University Hospital, Finnbladder | Bladder Cancer | 11/25 | 11/25 | | |
EVER, NCT05037279: Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) |
|
|
| Not yet recruiting | 3 | 540 | NA | Bacillus Calmette-Guerin: Strain Russian BCG-I, Verity-BCG, Bacillus Calmette-Guerin: Strain TICE, OncoTICE | Verity Pharmaceuticals Inc. | Bladder Cancer, Bladder Cancer Recurrent, Neoplasm Recurrence, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent, Non-Invasive Bladder Urothelial Carcinoma | 12/25 | 01/26 | | |
KEYNOTE-676, NCT03711032 / 2018-001967-22: Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/) |
|
|
| Recruiting | 3 | 1397 | Europe, Canada, Japan, US, RoW | Pembrolizumab, KEYTRUDA®, MK-3475, BCG, TICE® BCG, OncoTICE® | Merck Sharp & Dohme LLC | High-risk Non-muscle Invasive Bladder Cancer | 12/25 | 10/28 | | |
|
|
NCT03928275: The Response to Intralesional IL-2 and/or BCG Treatment for Cutaneous Metastatic Melanoma |
|
|
| Withdrawn | 2/3 | 100 | NA | Interleukin-2, Proleukin (Aldesleukin), Combination therapy Interleukin-2 and Bacillus Calmette Guerin, BCG, strain TICE (OncoTICE) and Proleukin (Aldesleukin) | Carman Giacomantonio, Nova Scotia Health Authority | Cutaneous Metastatic Melanoma | 09/22 | 09/22 | | |
COV19-DS, NCT03348670: Pharmacogenomics IND EXEMPT SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms |
|
|
| Active, not recruiting | 2/3 | 600 | US | Abiraterone - Usual, ZYTIGA - abiraterone acetate tablet, film coated plus RAYOS - prednisone tablet, delayed release plus ORGOVYX - relugolix tablet, film coated for Oral, Abiraterone - Study, ZYTIGA - abiraterone acetate tablet plus RAYOS - prednisone tablet, delayed release plus ORGOVYX - relugolix tablet, film coated for Oral | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | Prostate Cancer | 05/24 | 05/24 | | |
NCT04884308: Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections |
|
|
| Completed | 2 | 29 | US | BCG TICE Vaccine | Johns Hopkins University, Cystic Fibrosis Foundation | Cystic Fibrosis, Bronchiectasis Adult, Non-Tuberculous Mycobacteria | 12/23 | 12/23 | | |
2011-000607-41: A phase I/II multicentric Belgian prospective novel sequential chemo-immunotherapy regimen for adjuvant treatment in non-muscle invasive bladder cancer. |
|
|
| Ongoing | 1/2 | 60 | Europe | Mitomycine C, Oncotice, Mitomycine C 20 mg, Oncotice (Bacillus Calmette guérin), Mitomycine C 20 mg, Oncotice (Bacillus Calmette guérin) | Centre Hospitalier de Jolimont-Lobbes-Tubize-Nivelles | Patients with intermediate/high risk non-muscle invasive bladder cancer (NMIBC)• intermediate risk tumours – Ta, T1 Grade 1, Grade 2, multifocal and tumours larger than 3 cm• high risk tumours – T1, Grade 3, multifocal or highly recurrent tumours and all cases of CIS (Carcinoma in situ) | | | | |
NU 15U06, NCT02808143: Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer |
|
|
| Completed | 1 | 9 | US | BCG Solution, Bacillus Calmette-Guerin Solution, TICE BCG Solution, Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Pharmacological Study | Northwestern University, Merck Sharp & Dohme LLC, National Cancer Institute (NCI) | Recurrent Bladder Carcinoma, Stage 0a Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Cancer | 05/20 | 08/22 | | |
